FGL (Fibroblast Growth Loop)

FGL (FG Loop peptide) is a synthetic 15-amino-acid tetrameric dendrimer derived from the FG loop region of the second fibronectin type III (FNIII) module of the neural cell adhesion molecule (NCAM). This segment corresponds to the precise binding site through which NCAM interacts with the immunoglobulin-like domain 3 (Ig3) of fibroblast growth factor receptor 1 (FGFR1).

By directly engaging FGFR1, FGL activates downstream intracellular cascades associated with neuronal survival, neurite outgrowth, and synaptic remodeling. A key effector identified in hippocampal preparations is protein kinase C (PKC), which upon activation drives activity-dependent insertion of AMPA-type glutamate receptors into excitatory synapses at CA1 hippocampal neurons. This receptor trafficking mechanism is considered responsible for the long-term enhancement of synaptic transmission observed in slice culture studies and the memory improvements documented in rodent behavioral assays.

Beyond synaptic modulation, FGL promotes neural stem cell (NSC) proliferation in the subventricular zone and hippocampus and preferentially steers NSC differentiation toward an oligodendroglial fate, suggesting a distinct role in remyelination. The peptide also attenuates neuroinflammation via an increase in CD200 expression on astrocytes; CD200 ligates its cognate microglial receptor to maintain microglia in a quiescent, non-activated state, thereby reducing production of IL-1beta, IL-6, and TNF-alpha.

• Primary receptor target: FGFR1 (allosteric modulation) • Key intracellular effectors: PKC, GSK3beta inhibition (pSer9), HIF-1alpha • Net downstream effects: AMPA receptor synaptic delivery, neuroplasticity, NSC mobilization, anti-inflammatory microglial regulation

The evidence base for FGL is predominantly preclinical, consisting of in vitro cell culture and rodent or gerbil in vivo studies, with a single small Phase I human safety study. No completed Phase II or Phase III randomized controlled trials have been published.

Preclinical neuroprotection: A published study (Akhtar et al., Neuropharmacology, 2005; PMID 16197499) demonstrated that FGL protected rat hippocampal neurons subjected to oxygen-glucose deprivation in vitro and significantly reduced CA1 pyramidal cell death in a gerbil transient global ischemia model when injected suboccipitally either before or after the insult.

Cognitive and synaptic effects: Esteban et al. (PLoS Biology, 2012) found that FGL at 10 micrograms/mL applied to hippocampal slice cultures enhanced activity-dependent LTP by approximately twofold relative to untreated slices, and that intra-hippocampal administration improved performance in fear conditioning, social learning, motor learning, and Morris water maze tasks in rats, with effects persisting up to two weeks. Ultrastructural studies in aged rats (22 months old) receiving subcutaneous FGL at 8 mg/kg every two days for 19 days showed a significant shift from thin to mushroom-type dendritic spines and remodeling of postsynaptic densities in the dentate gyrus, correlating with previously reported LTP improvements.

Alzheimer's model: A rat study (PMID 17223274) in which amyloid-beta25-35 was administered intracerebroventricularly found that FGL given intracisternally, intranasally, or subcutaneously prevented or attenuated amyloid deposition, tau phosphorylation, microglial activation, and memory impairment, with protective effects attributed in part to GSK3beta inhibition.

Neural stem cell mobilization: Tfilin et al. (PubMed 24817672, 2014) showed that FGL at 10 micrograms/mL maximally enhanced NSC proliferation in vitro and that subcutaneous injection in adult rats increased NSC proliferative activity in the subventricular zone as confirmed by PET imaging.

Kindling seizure model: A 2014 mouse study (PMC3963124) using FGL at 2 mg/kg and 10 mg/kg subcutaneously found the unexpected result that both doses significantly accelerated progression to generalized seizures in the amygdala kindling model; the authors raised concern about a possible pro-epileptogenic effect on hyperexcitable networks and called for further evaluation.

Human Phase I data: An open-label, ascending-dose, Phase I study published in Clinical Pharmacokinetics (2007, PMID 17375985) enrolled 24 healthy male volunteers (mean age 42 years, range 24-55). Single intranasal doses of 25, 100, and 200 mg of a modified form (FGLL) were well tolerated with no clinically notable ECG, vital sign, or laboratory abnormalities. Quantifiable plasma concentrations were detectable up to 4 hours after the 200 mg dose (mean Cmax 1.38 ng/mL). No Phase II efficacy data in patients have been published.

The EU-funded NeuroFGL consortium (FP7, 2012-2014; budget approximately 7.8 million euros) completed toxicology studies that established a no-observed-adverse-effect level of 1000 mg/kg/day in non-rodent species; the planned Phase II proof-of-concept trial in early Alzheimer's disease patients was not completed within the funding period. No subsequent trial registration or publication is identifiable in public registries as of mid-2026.

Typical dosage: 100 mcg (daily).

The following dosage information is drawn from preclinical animal studies and a single small Phase I human trial; no regulatory-approved dosing regimen exists for FGL.

Animal studies (rodent): • Subcutaneous injection: 0.2 mg/kg to 10 mg/kg, administered once daily or every two days depending on the study. A dose of 8 mg/kg subcutaneously every two days for 19 days was used in aged-rat synapse studies. Doses of 2 and 10 mg/kg subcutaneously five times per week were used in the mouse kindling model. • Intranasal: 0.2, 0.8, or 3.2 mg/kg daily in rat amyloid-beta models. The minimum effective dose for neuroprotection in rodents is reported as approximately 0.2 mg/kg; for social recognition memory deficits the minimum effective dose is approximately 0.8 mg/kg. • Intracerebroventricular (research use only): single doses used in memory consolidation studies immediately post-training.

Pharmacokinetics: Following subcutaneous administration in rats, FGL is detectable in cerebrospinal fluid within 10 minutes and maintains stable CNS concentrations for up to 5 hours. Plasma half-life is approximately 4-6 hours. The peptide crosses the blood-brain barrier and was confirmed in human CSF after intranasal dosing.

Human Phase I (FGLL, modified form): Single intranasal doses of 25, 100, and 200 mg in 24 healthy males were the only studied human doses; all were well tolerated. No multi-dose human regimen has been published.

Community or compounding use: Some vendors and non-clinical sources report research doses of 1-5 mg subcutaneously on a periodic basis (e.g., every other day or several times weekly), but these protocols are not supported by published human clinical data.

This information is provided for educational and reference purposes only and does not constitute medical advice. FGL has no approved therapeutic indication and no established safe or effective dosing in humans beyond the single-dose Phase I safety study.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

No published human clinical trial has evaluated FGL in combination with any other compound. The following combinations are discussed in anecdotal or theoretical contexts in community and non-peer-reviewed sources, and should be treated as speculative.

• FGL with other FGFR-activating peptides (e.g., P6): Hypothetically additive effects on neuroplasticity through shared FGFR signaling, but no published evidence supports this combination in any species.

• FGL with BDNF-mimetic or neurotrophic peptides (e.g., Dihexa, Cerebrolysin): Proposed on the basis of complementary mechanisms (FGFR vs. TrkB signaling), but no preclinical or clinical combination data exist. This combination rationale is anecdotal.

• FGL with anti-inflammatory compounds (e.g., BPC-157, TB-500): Suggested by some in the research-peptide community to enhance anti-neuroinflammatory effects; no peer-reviewed study has examined this. Anecdotal only.

• Intranasal formulation with absorption enhancers: The NeuroFGL consortium explored formulation optimization for intranasal delivery; no specific co-excipient recommendation is available in public literature.

Given that a mouse seizure model raised concern about possible pro-epileptogenic effects at the doses tested, combining FGL with other compounds that lower seizure threshold would carry additional theoretical risk. Any combined use outside a clinical trial setting is unsupported by evidence and not recommended.

FGL (Fibroblast Growth Loop) is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Minimal side effects

Preclinical safety: Toxicology studies conducted as part of the EU NeuroFGL project (2012-2014) found a no-observed-adverse-effect level (NOAEL) of 1000 mg/kg/day in non-rodent species, approximately 20-fold higher than anticipated. Experiments in rats, dogs, and non-human primates reported no toxic effects at pharmacologically relevant doses. In the mouse kindling study (PMC3963124), one animal in the 2 mg/kg FGL group died during the kindling procedure on day 12 and one animal in the 10 mg/kg group was euthanized due to deteriorating general condition; the authors noted these events did not appear attributable to FGL but acknowledged the possibility could not be fully excluded.

Seizure concern: The most significant safety signal from preclinical research is the finding in the mouse amygdala kindling model that both 2 mg/kg and 10 mg/kg FGL significantly accelerated progression to generalized seizures compared to scrambled control peptide. The authors explicitly raised concern about a "putative effect which might promote the formation of a hyperexcitable network." This finding has not been replicated or refuted in spontaneous seizure models and constitutes an unresolved safety question. FGL should be used with particular caution in individuals with any history of seizure disorder.

Human Phase I (FGLL, modified form): In the single published human study (Clinical Pharmacokinetics, 2007), 24 healthy male volunteers received single intranasal doses of 25, 100, and 200 mg without any clinically notable adverse events on ECG, vital signs, or laboratory parameters over an 8-day observation period. The study was limited to single doses in healthy young-to-middle-aged men with no disease burden.

Theoretical concerns: • Stimulation of FGFR signaling could theoretically promote proliferation of FGFR-expressing tumor cells; this has not been examined in clinical populations. • NSC mobilization and oligodendroglial differentiation effects have unknown long-term consequences. • There are no data in pregnant or lactating individuals, pediatric or geriatric populations beyond the aged-rat model, or individuals with hepatic or renal impairment.

FGL has no FDA, EMA, or any other regulatory approval. It is not approved for any therapeutic indication. Self-administration outside of a supervised clinical context carries unknown risk.